DK2346888T3 - Fremgangsmåde til fremstilling af som SGLT-inhibitorer anvendelige forbindelser - Google Patents

Fremgangsmåde til fremstilling af som SGLT-inhibitorer anvendelige forbindelser

Info

Publication number: DK2346888T3
Authority: DK; Denmark
Prior art keywords: preparation; compounds useful; sglt inhibitors; sglt; inhibitors
Prior art date: 2008-10-17

Application number

DK09736928.4T

Other languages

English (en)

Inventor

Walter Ferdinand Maria Filliers

Rudy Laurent Maria Broeckx

Patrick Hubert J Nieste

Masanori Hatsuda

Masahiko Yoshinaga

Mitsuhiro Yada

Christopher Teleha

Original Assignee

Janssen Pharmaceutica Nv

Mitsubishi Tanabe Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-17

Filing date

2009-10-15

Publication date

2013-03-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42106967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2346888(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-10-15 Application filed by Janssen Pharmaceutica Nv, Mitsubishi Tanabe Pharma Corp filed Critical Janssen Pharmaceutica Nv

2013-03-25 Application granted granted Critical

2013-03-25 Publication of DK2346888T3 publication Critical patent/DK2346888T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/12—Radicals substituted by halogen atoms or nitro or nitroso radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Obesity (AREA)
Hematology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

DK09736928.4T 2008-10-17 2009-10-15 Fremgangsmåde til fremstilling af som SGLT-inhibitorer anvendelige forbindelser DK2346888T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US10626008P	2008-10-17	2008-10-17
US10623108P	2008-10-17	2008-10-17
US12/578,934 US9056850B2 (en)	2008-10-17	2009-10-14	Process for the preparation of compounds useful as inhibitors of SGLT
PCT/EP2009/063503 WO2010043682A2 (en)	2008-10-17	2009-10-15	Process for the preparation of compounds useful as inhibitors of sglt

Publications (1)

Publication Number	Publication Date
DK2346888T3 true DK2346888T3 (da)	2013-03-25

Family

ID=42106967

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK12156039.5T DK2457908T3 (da)	2008-10-17	2009-10-15	Fremgangsmåde til fremstillingen af forbindelser der er anvendelige som inhibitorer af SGLT
DK12156035.3T DK2455374T3 (da)	2008-10-17	2009-10-15	Fremgangsmåde til fremstillingen af forbindelser der kan anvendes som inhibitorer af SGLT
DK09736928.4T DK2346888T3 (da)	2008-10-17	2009-10-15	Fremgangsmåde til fremstilling af som SGLT-inhibitorer anvendelige forbindelser

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DK12156039.5T DK2457908T3 (da)	2008-10-17	2009-10-15	Fremgangsmåde til fremstillingen af forbindelser der er anvendelige som inhibitorer af SGLT
DK12156035.3T DK2455374T3 (da)	2008-10-17	2009-10-15	Fremgangsmåde til fremstillingen af forbindelser der kan anvendes som inhibitorer af SGLT

Country Status (30)

Country	Link
US (1)	US9056850B2 (da)
EP (3)	EP2455374B1 (da)
JP (3)	JP6123111B2 (da)
KR (2)	KR101679593B1 (da)
CN (3)	CN103467439B (da)
AR (1)	AR073892A1 (da)
AU (1)	AU2009305413B2 (da)
BR (1)	BRPI0920356B1 (da)
CA (2)	CA2740853C (da)
CL (1)	CL2011000849A1 (da)
CY (3)	CY1113867T1 (da)
DK (3)	DK2457908T3 (da)
EA (1)	EA021373B1 (da)
ES (3)	ES2854598T3 (da)
HK (1)	HK1224289A1 (da)
HR (3)	HRP20130254T1 (da)
HU (2)	HUE030868T2 (da)
IL (2)	IL212270A0 (da)
LT (2)	LT2455374T (da)
MX (1)	MX2011004054A (da)
NZ (1)	NZ592204A (da)
PL (3)	PL2455374T3 (da)
PT (3)	PT2346888E (da)
RS (3)	RS61484B1 (da)
SI (3)	SI2457908T1 (da)
SM (2)	SMT201300058B (da)
TW (3)	TW201613905A (da)
UA (1)	UA107450C2 (da)
WO (1)	WO2010043682A2 (da)
ZA (1)	ZA201103587B (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5596545B2 (ja) *	2007-09-10	2014-09-24	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｓｇｌｔの阻害物質として有用な化合物の製造方法
US9056850B2 (en) *	2008-10-17	2015-06-16	Janssen Pharmaceutica N.V.	Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en)	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
EA022186B1 (ru)	2009-07-10	2015-11-30	Янссен Фармацевтика Нв	СПОСОБ КРИСТАЛЛИЗАЦИИ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-4-МЕТИЛ-3-[5-(4-ФТОРФЕНИЛ)-2-ТИЕНИЛМЕТИЛ]БЕНЗОЛА
UA109883C2 (uk) *	2009-10-14	2015-10-26		Спосіб отримання сполук для застосування як інгібіторів sglt2
US8163704B2 (en)	2009-10-20	2012-04-24	Novartis Ag	Glycoside derivatives and uses thereof
SG185525A1 (en) *	2010-05-11	2012-12-28	Janssen Pharmaceutica Nv	Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
WO2012006298A2 (en) *	2010-07-06	2012-01-12	Janssen Pharmaceutica Nv	Formulation for co-therapy treatment of diabetes
KR101913587B1 (ko) *	2011-04-13	2018-10-31	얀센 파마슈티카 엔.브이.	Sglt2의 억제제로서 유용한 화합물의 제조 방법
US9035044B2 (en)	2011-05-09	2015-05-19	Janssen Pharmaceutica Nv	L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
WO2013152476A1 (en) *	2012-04-10	2013-10-17	Theracos, Inc.	Process for the preparation of benzylbenzene sglt2 inhibitors
US9193751B2 (en)	2012-04-10	2015-11-24	Theracos, Inc.	Process for the preparation of benzylbenzene SGLT2 inhibitors
EP2994468B1 (en)	2013-05-08	2017-07-19	LEK Pharmaceuticals d.d.	Crystalline hydrates of 1-(beta-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene
CN104418834B (zh) *	2013-08-23	2017-09-15	重庆博腾制药科技股份有限公司	一种抗糖尿病药物中间体的合成方法
CN104418847A (zh) *	2013-09-10	2015-03-18	天津药物研究院	4-(6-脱氧-β-D-吡喃葡萄糖基)-2-[5-(4-氟苯基)噻吩-2-甲基]-1-甲基苯的制备工艺
CN103601715B (zh) *	2013-11-22	2015-08-19	沈阳化工大学	一种2-(4-氟苯基)噻吩的分离提纯方法
EP2918579A1 (en)	2014-03-14	2015-09-16	LEK Pharmaceuticals d.d.	Synthesis of 2-arylmethyl-5-aryl-thiophene
EP2933255A1 (en)	2014-04-17	2015-10-21	LEK Pharmaceuticals d.d.	Novel crystalline form of 1-(beta-D-glucopyranosyl)-4- methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene
EP3148979B1 (en) *	2014-05-27	2019-02-06	Glenmark Pharmaceuticals Limited	Process for preparation of canagliflozin
CN105330706B (zh) *	2014-06-05	2019-04-16	江苏豪森药业集团有限公司	卡格列净中间体的制备方法
CN104119324B (zh) *	2014-07-23	2016-03-30	齐鲁天和惠世制药有限公司	一种卡格列净的制备方法
CN104292209A (zh) *	2014-09-11	2015-01-21	浙江丽晶化学有限公司	一种制备2-(4-氟苯基)噻吩(化合物v)的新方法
CN104402946B (zh) *	2014-11-17	2018-01-02	连云港恒运药业有限公司	卡格列净中间体及其无定形的制备方法
WO2016083790A1 (en) *	2014-11-25	2016-06-02	Cipla Limited	Process for the preparation of canagliflozin
CN105753910A (zh) *	2014-12-16	2016-07-13	康普药业股份有限公司	一种卡格列净中间体的制备方法
CN105753827A (zh) *	2014-12-17	2016-07-13	中美华世通生物医药科技（武汉）有限公司	制备化合物的方法
WO2016128995A1 (en)	2015-02-09	2016-08-18	Indoco Remedies Limited	Process for the preparation of sglt inhibitor compounds
WO2016132355A1 (en) *	2015-02-16	2016-08-25	B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University	Introduction of alkyl substituents to aromatic compounds
WO2016135747A2 (en) *	2015-02-27	2016-09-01	Msn Laboratories Private Limited	Process for the preparation of amorphous (1s)-1,5-anhvdro-1-[3-[[5-(4 fluorophennyl)-2-thienyl]methvl]-4-methylphenyl]-d-glucitol and its polymorphs thereof
JP6916740B2 (ja)	2015-05-22	2021-08-11	ヤンセンファーマシューティカエヌ．ベー．	（１ｓ）−１，５−アンヒドロ−１−［３−［［５−（４−フルオロフェニル）−２−チエニル］メチル］−４−メチルフェニル］−ｄ−グルシトールの無水結晶形
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CZ2015729A3 (cs)	2015-10-13	2017-04-26	Zentiva, K.S.	Příprava intermediátů pro syntézu Canagliflozinu a Dapagliflozinu
CN106938998B (zh) *	2017-04-07	2018-07-03	四川智强医药科技开发有限公司	卡格列净有关物质的合成方法
CN110869380A (zh)	2017-05-09	2020-03-06	皮拉马尔企业有限公司	用于制备sglt2抑制剂和其中间体的方法
CN109553609B (zh) *	2017-09-26	2020-09-04	北大方正集团有限公司	一种卡格列净的制备方法
JP7046868B2 (ja) *	2018-05-31	2022-04-04	株式会社トクヤマ	ジアリールメタン化合物の製造方法
TWI788573B (zh)	2018-05-31	2023-01-01	日商德山股份有限公司	二芳基甲烷化合物之製造方法
TW202024046A (zh) *	2018-09-06	2020-07-01	日商德山股份有限公司	β－Ｃ－芳基糖苷衍生物的製造方法
CN109180662A (zh) *	2018-10-17	2019-01-11	北大医药股份有限公司	一种卡格列净的制备方法
TW202039428A (zh) *	2018-12-17	2020-11-01	日商德山股份有限公司	Ｃ－芳基羥基二醇化物（Ｃ－Ａｒｙｌｈｙｄｒｏｘｙｇｌｙｃｏｘｉｄｅ）衍生物之製造方法
JP2022028986A (ja) *	2018-12-17	2022-02-17	株式会社トクヤマ	Ｃ－アリールヒドロキシグリコキシド誘導体の製造方法
CN110698468B (zh) *	2019-09-24	2020-11-03	杭州华东医药集团新药研究院有限公司	一种坎格列净的制备方法
CN111057049B (zh) *	2019-11-18	2021-06-01	杭州华东医药集团新药研究院有限公司	一种卡格列净半水化合物的制备方法
CN113943329A (zh) *	2020-07-16	2022-01-18	尚科生物医药（上海）有限公司	一种坎格列净中间体的非对映异构体的制备方法
US20240025873A1 (en)	2020-11-18	2024-01-25	Tokuyama Corporation	Method for producing ketone derivative
CN112608299A (zh) *	2020-12-24	2021-04-06	山东铂源药业有限公司	一种4-(6-氨基吡啶-3-基)哌啶-1-甲酸叔丁酯的合成方法
CN113372326A (zh) *	2021-06-23	2021-09-10	江苏法安德医药科技有限公司	一种2-(4-氟苯基)噻吩的分离提纯方法
CN113429379A (zh) *	2021-06-28	2021-09-24	江苏法安德医药科技有限公司	一种lh-1801中间体及其制备方法和应用
WO2023080243A1 (ja) *	2021-11-08	2023-05-11	株式会社トクヤマ	Ｃ－アリールグリコサイド誘導体の製造方法
CN115557940B (zh) *	2022-12-06	2023-06-20	恒升德康(南京)医药科技有限公司	一种利用微通道反应器连续化生产卡格列净的方法
CN116789716A (zh) *	2023-06-26	2023-09-22	南京科默生物医药有限公司	一种达格列净和艾托格列净中间体的制备方法

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2799241A (en)	1949-01-21	1957-07-16	Wisconsin Alumni Res Found	Means for applying coatings to tablets or the like
US4160861A (en)	1977-10-03	1979-07-10	Merck & Co., Inc.	Method for the separation of antibiotic macrolides
US4584369A (en)	1981-07-31	1986-04-22	Sloan-Kettering Institute For Cancer Research	Anti-leukemic beta-glycosyl C-nucleosides
JPS5939889A (ja)	1982-08-30	1984-03-05	Noguchi Kenkyusho	２，４，６↓−トリ↓−０↓−アセチル↓−３↓−デオキシ↓−ヘキソノ↓−１，５↓−ラクトンの製造方法
JP2544609B2 (ja)	1986-10-07	1996-10-16	和光純薬工業株式会社	Ｔｃｎｑ錯体
US4863957A (en)	1987-12-21	1989-09-05	Rorer Pharmaceutical Corporation	Novel HMG-CoA reductase inhibitors
CA1327013C (en)	1988-06-23	1994-02-15	Peter Rex Brawn	Cosmetic composition
ES2067508T3 (es)	1988-08-19	1995-04-01	Warner Lambert Co	Dihidroisoquinolinonas sustituidas y compuestos relacionados como potenciadores de los efectos letales de la radiacion y de ciertos agentes quimioterapeuticos; compuestos seleccionados, analogos y proceso.
ATE123237T1 (de)	1990-08-24	1995-06-15	Spirig Ag	Verfahren zur herstellung von pellets.
JPH04253974A (ja)	1991-02-05	1992-09-09	Ishihara Sangyo Kaisha Ltd	スルホニル尿素系化合物、それらの製造方法及びそれらを含有する除草剤
EP0517969A1 (en)	1991-06-10	1992-12-16	AUSIMONT S.p.A.	Process for increasing the bleaching efficiency of an inorganic persalt or of hydrogen peroxide
US5149838A (en)	1991-09-20	1992-09-22	Merck & Co., Inc.	Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents
US5610294A (en)	1991-10-11	1997-03-11	The Du Pont Merck Pharmaceutical Company	Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
MX9205392A (es)	1991-10-29	1993-04-01	Du Pont	Triazolcarbozamidas herbicidas y procedimiento para su obtencion.
GB9208161D0 (en)	1992-04-14	1992-05-27	Pfizer Ltd	Indoles
US5334225A (en)	1992-07-15	1994-08-02	Kao Corporation	Keratinous fiber dye composition containing a 2-substituted amino-5-alkylphenol derivative coupler
US5731292A (en)	1992-11-12	1998-03-24	Tanabe Seiyaku Co., Ltd.	Dihydrochalcone derivatives which are hypoglycemic agents
CA2102591C (en)	1992-11-12	2000-12-26	Kenji Tsujihara	Hypoglycemic agent
DE4243279A1 (de)	1992-12-21	1994-06-23	Bayer Ag	Substituierte Triole
US6297363B1 (en)	1993-02-12	2001-10-02	Nomura Co., Ltd.	Glycoside indoles
JPH06256354A (ja)	1993-03-01	1994-09-13	Nippon Nohyaku Co Ltd	新規テトラゾール化合物及びその製法
JP3187611B2 (ja)	1993-05-17	2001-07-11	キヤノン株式会社	液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置
JPH07242526A (ja)	1994-03-03	1995-09-19	Sogo Yatsukou Kk	化粧料
US5830873A (en)	1994-05-11	1998-11-03	Tanabe Seiyaku Co., Ltd.	Propiophenone derivative and a process for preparing the same
EP0732921A4 (en)	1994-09-30	1998-09-02	Ohio State Res Found	C-GLYCOSIDANOLOGIST OF N- (4-HYDROXYPHENYL) RETINAMIDE-O-GLUCURONIDE
US5780483A (en)	1995-02-17	1998-07-14	Smithkline Beecham Corporation	IL-8 receptor antagonists
ATE284690T1 (de)	1995-10-31	2005-01-15	Lilly Co Eli	Antithrombotische diamine
JP3059088B2 (ja)	1995-11-07	2000-07-04	田辺製薬株式会社	プロピオフェノン誘導体およびその製法
US5723495A (en)	1995-11-16	1998-03-03	The University Of North Carolina At Chapel Hill	Benzamidoxime prodrugs as antipneumocystic agents
JPH09263549A (ja)	1996-01-25	1997-10-07	Fujisawa Pharmaceut Co Ltd	ベンゼン誘導体の製造法
IL121525A0 (en)	1996-08-26	1998-02-08	Tanabe Seiyaku Co	Process for preparing optically active benzothiazepine compound and intermediate therefor
PT850948E (pt)	1996-12-26	2002-08-30	Tanabe Seiyaku Co	Derivados propiofenona e processo para a preparacao dos mesmos
US6153632A (en)	1997-02-24	2000-11-28	Rieveley; Robert B.	Method and composition for the treatment of diabetes
AU6422298A (en)	1997-03-25	1998-10-20	Takeda Chemical Industries Ltd.	Pharmaceutical composition containing a phosphorylamide and an ayntibiotic
AP1224A (en)	1998-03-19	2003-11-14	Bristol Myers Squibb Co	Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
EP1087931A1 (de)	1998-06-18	2001-04-04	MERCK PATENT GmbH	Verfahren zur symmetrischen und unsymmetrischen disubstitution von carbonsäureamiden mit organotitanaten und grignard-reagenzien
FR2780403B3 (fr)	1998-06-24	2000-07-21	Sanofi Sa	Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
JP2000034239A (ja)	1998-07-16	2000-02-02	Asahi Glass Co Ltd	トリフルオロメチル化芳香族化合物の製造方法
JP3857429B2 (ja)	1998-07-17	2006-12-13	ポーラ化成工業株式会社	含硫黄抗真菌剤
US6069238A (en)	1998-09-30	2000-05-30	Eli Lilly And Company	Spirocyclic C-glycosides
JP2002529455A (ja)	1998-11-09	2002-09-10	ジェームズ・ブラック・ファウンデーション・リミテッド	ガストリンおよびコレシストキニン受容体リガンド類
PL347634A1 (en)	1998-11-12	2002-04-22	Smithkline Beecham Plc	Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20020032164A1 (en)	1998-12-30	2002-03-14	Dale Roderic M. K.	Antimicrobial compounds and methods for their use
GB9912961D0 (en)	1999-06-03	1999-08-04	Pfizer Ltd	Metalloprotease inhibitors
US6515117B2 (en)	1999-10-12	2003-02-04	Bristol-Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en)	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
CA2389928C (en)	1999-11-03	2010-03-23	Bristol-Myers Squibb Company	Method for treating diabetes
JP3450810B2 (ja)	2000-01-31	2003-09-29	キヤノン株式会社	脂肪族ポリエステル、脂肪族ポリエステルの製造方法およびセルロースの再資源化方法
US6627611B2 (en)	2000-02-02	2003-09-30	Kotobuki Pharmaceutical Co Ltd	C-glycosides and preparation of thereof as antidiabetic agents
JP4456768B2 (ja)	2000-02-02	2010-04-28	壽製薬株式会社	Ｃ−配糖体を含有する薬剤
AU2001232175B2 (en)	2000-03-03	2005-07-07	Pfizer Products Inc.	Pyrazole ether derivatives as anti-inflammatory/analgesic agents
JP3773450B2 (ja)	2000-03-17	2006-05-10	キッセイ薬品工業株式会社	グルコピラノシルオキシベンジルベンゼン誘導体、それを含有する医薬組成物およびその製造中間体
US6683056B2 (en)	2000-03-30	2004-01-27	Bristol-Myers Squibb Company	O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en)	2000-03-30	2003-04-29	Bristol-Myers Squibb Company	O-glucosylated benzamide SGLT2 inhibitors and method
GB0011098D0 (en)	2000-05-08	2000-06-28	Black James Foundation	Pharmaceutical compositions comprising protpn pump inhibitors and gastrin/cholecystokinin receptor ligands
EP1172362A1 (de)	2000-07-11	2002-01-16	Basf Aktiengesellschaft	Azadioxacycloalkene und ihre Verwendung zur Bekämpfung von Schadpilzen und tierischen Schädlingen
KR100426030B1 (ko)	2000-07-22	2004-04-03	(주) 한켐	락톤계 당화합물에서의 키랄성 전환방법
US6784167B2 (en)	2000-09-29	2004-08-31	Bayer Pharmaceuticals Corporation	17-beta-hydroxysteroid dehydrogenase-II inhibitors
DE60141156D1 (de)	2000-11-02	2010-03-11	Ajinomoto Kk	Neue pyrazolderivate und diese enthaltende mittel gegen diabetes
JP2002167430A (ja)	2000-12-01	2002-06-11	Canon Inc	脂肪族ポリエステル、脂肪族ポリエステルの製造方法およびデンプンの資源化方法
US6476352B2 (en)	2000-12-18	2002-11-05	General Electric Company	Laser beam stop sensor and method for automatically detecting the presence of laser beam stop material using a laser beam stop sensor
AU2002225356B2 (en)	2000-12-28	2008-03-06	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxypyrazole derivatives and use thereof in medicines
JP4141258B2 (ja)	2001-02-26	2008-08-27	キッセイ薬品工業株式会社	グルコピラノシルオキシピラゾール誘導体及びその医薬用途
US7294618B2 (en)	2001-02-27	2007-11-13	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxypyrazole derivatives and medicinal use thereof
EP1363954B1 (en)	2001-03-02	2012-10-17	University of Western Ontario	Polymer precursors of radiolabeled compounds, and methods of making and using the same
US6936590B2 (en)	2001-03-13	2005-08-30	Bristol Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
ES2258141T3 (es)	2001-04-11	2006-08-16	Bristol-Myers Squibb Company	Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
CA2445346C (en)	2001-04-27	2010-04-06	Ajinomoto Co., Inc.	N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same
GB0112122D0 (en)	2001-05-18	2001-07-11	Lilly Co Eli	Heteroaryloxy 3-substituted propanamines
US7105556B2 (en)	2001-05-30	2006-09-12	Bristol-Myers Squibb Company	Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
US7271153B2 (en)	2001-06-20	2007-09-18	Kissei Pharmaceutical Co., Ltd.	Nitrogenous heterocyclic derivatives, medicinal compositions containing the same, medicinal uses thereof, and intermediates therefor
JP4115105B2 (ja)	2001-07-02	2008-07-09	協和醗酵工業株式会社	ピラゾール誘導体
JPWO2003011880A1 (ja)	2001-07-31	2004-11-18	キッセイ薬品工業株式会社	グルコピラノシルオキシベンジルベンゼン誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
US20030191121A1 (en)	2001-08-09	2003-10-09	Miller Ross A.	Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
WO2003020737A1 (en)	2001-09-05	2003-03-13	Bristol-Myers Squibb Company	O-pyrazole glucoside sglt2 inhibitors and method of use
ATE316148T1 (de)	2001-10-24	2006-02-15	Michael Burton	Enzymsubstrate zum nachweis der beta-d- ribofuranosidase aktivität
JP2005510518A (ja) *	2001-11-08	2005-04-21	セプラコール，インク．	シタロプラムのデスメチル代謝産物及びジデスメチル代謝産物の濃縮された鏡像異性体を用いてうつ病及び他のｃｎｓ障害を治療する方法
CN1589136A (zh)	2001-11-16	2005-03-02	古泰尼斯公司	含有携带含氧基团的芳族醛的药物与化妆品组合物
JP2003238417A (ja)	2002-02-18	2003-08-27	Nippon Shoyaku Kenkyusho:Kk	フロレチン配糖体の安定化組成物、該安定化組成物を含有する糖尿病予防・治療剤、および保健食品
US6617313B1 (en)	2002-03-13	2003-09-09	Council Of Scientific And Industrial Research	Glucopyranoside and process of isolation thereof from pterocarpus marsupium pharmaceutical composition containing the same and use thereof
US6562791B1 (en)	2002-03-29	2003-05-13	Council Of Scientific And Industrial Research	Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
JP2003313168A (ja)	2002-04-18	2003-11-06	Kirin Brewery Co Ltd	Ｂｃｌ−２阻害活性を有する化合物およびその化合物のスクリーニング方法
ES2326638T3 (es)	2002-04-18	2009-10-16	Astrazeneca Ab	Compuestos heterociclicos.
DE10231370B4 (de)	2002-07-11	2006-04-06	Sanofi-Aventis Deutschland Gmbh	Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en)	2002-08-05	2006-05-11	Yamanouchi Pharma Co Ltd	Azulene derivative and salt thereof
MXPA04009265A (es)	2002-08-09	2005-01-25	Taisho Pharma Co Ltd	Derivados de aril 5-tio-beta-d-glucopiranosido y agentes terapeuticos para diabetes que contienen los mismos.
JP4606876B2 (ja)	2002-08-27	2011-01-05	キッセイ薬品工業株式会社	ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
EP1551384A4 (en)	2002-10-07	2008-04-09	Encore Pharmaceuticals Inc	R-NSAID ESTERS AND ITS USE
DE10258008B4 (de)	2002-12-12	2006-02-02	Sanofi-Aventis Deutschland Gmbh	Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de)	2002-12-12	2006-02-09	Sanofi-Aventis Deutschland Gmbh	Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
WO2004063209A2 (en)	2003-01-03	2004-07-29	Bristol-Myers Squibb Company	Methods of producing c-aryl glucoside sglt2 inhibitors
WO2004076470A2 (en)	2003-02-27	2004-09-10	Bristol-Myers Squibb Company	A non-cryogenic process for forming glycosides
PL1980560T3 (pl)	2003-03-14	2011-11-30	Astellas Pharma Inc	Pochodne C-glikozydowe do leczenia cukrzycy
JP2004300102A (ja)	2003-03-31	2004-10-28	Kissei Pharmaceut Co Ltd	縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
AU2003902263A0 (en)	2003-05-12	2003-05-29	Fujisawa Pharmaceutical Co., Ltd.	Monosaccharide compounds
EP1637539B1 (en)	2003-06-20	2012-01-18	Kissei Pharmaceutical Co., Ltd.	Pyrazole derivative, drug composition containing the same and production intermediate therefor
CN1826120A (zh)	2003-07-23	2006-08-30	幸讬制药公司	用于发炎与免疫相关用途的化合物
CA2549017A1 (en)	2003-08-01	2005-02-10	Mona Patel	Substituted indazole-o-glucosides
TW200521131A (en)	2003-08-01	2005-07-01	Janssen Pharmaceutica Nv	Substituted fused heterocyclic c-glycosides
EA010422B1 (ru)	2003-08-01	2008-08-29	Янссен Фармацевтика Н.В.	Замещённые индол-о-глюкозиды
UA86042C2 (en)	2003-08-01	2009-03-25	Янссен Фармацевтика Н.В.	Substituted indazole-o-glucosides
AR045173A1 (es)	2003-08-01	2005-10-19	Tanabe Seiyaku Co	Compuestos que poseen actividad inhibitoria contra transportador de glucosa dependiente de sodio
EP1679966A4 (en)	2003-08-01	2009-05-27	Janssen Pharmaceutica Nv	BENZIMIDAZOLE-, BENZTRIAZOLE- AND BENZIMIDAZOLONE-SUBSTITUTED O-GLUCOSIDES
WO2005058845A2 (en)	2003-12-19	2005-06-30	Novo Nordisk A/S	Novel glucagon antagonists/inverse agonists
JP4181605B2 (ja)	2004-03-16	2008-11-19	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グルコピラノシル置換フェニル誘導体、該化合物を含有する医薬品及びその使用と製造方法
US7393836B2 (en)	2004-07-06	2008-07-01	Boehringer Ingelheim International Gmbh	D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
EP1773800A1 (de)	2004-07-27	2007-04-18	Boehringer Ingelheim International GmbH	D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006018150A1 (de)	2004-08-11	2006-02-23	Boehringer Ingelheim International Gmbh	D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
TW200637839A (en)	2005-01-07	2006-11-01	Taisho Pharmaceutical Co Ltd	1-thio-d-glucitol derivatives
WO2006082523A2 (en)	2005-01-25	2006-08-10	Aurobindo Pharma Limited	Pharmaceutical sustained release composition of metformin
AR053329A1 (es)	2005-01-31	2007-05-02	Tanabe Seiyaku Co	Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
WO2006089872A1 (en)	2005-02-23	2006-08-31	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted ( (hetero)arylethynyl-benzyd-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
DE602006011453D1 (de)	2005-04-15	2010-02-11	Boehringer Ingelheim Pharma	Glucopyranosyl-substituierte (heteroaryloxy-benzyl)-benzen-derivate als sglt-inhibitoren
US7772191B2 (en)	2005-05-10	2010-08-10	Boehringer Ingelheim International Gmbh	Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007014894A2 (en)	2005-07-27	2007-02-08	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted ( (hetero) cycloalyklethynyl-benzyl) -benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors
ATE484499T1 (de)	2005-08-30	2010-10-15	Boehringer Ingelheim Int	Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
AR056195A1 (es)	2005-09-15	2007-09-26	Boehringer Ingelheim Int	Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
TW200806641A (en)	2006-01-25	2008-02-01	Synta Pharmaceuticals Corp	Substituted aromatic compounds for inflammation and immune-related uses
JP2007230999A (ja)	2006-01-31	2007-09-13	Kyoto Univ	置換芳香族ニトリル化合物およびその製造方法
TWI418556B (zh)	2006-07-27	2013-12-11	Mitsubishi Tanabe Pharma Corp	吲哚衍生物
JP5384343B2 (ja)	2006-08-15	2014-01-08	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グルコピラノシル−置換シクロプロピルベンゼン誘導体、そのような化合物を含む医薬組成物、ｓｇｌｔ阻害剤としてのそれらの使用及びそれらの製造方法
WO2008034859A1 (en)	2006-09-21	2008-03-27	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
CL2007003187A1 (es)	2006-11-06	2008-03-07	Boehringer Ingelheim Int	Compuestos derivados de bencil-benzonitrilo sustituido con glucopiranosilo y sus sales; procedimiento de preparacion; compuestos intermediarios; proceso para preparar los compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de
EP3037095A3 (en)	2006-11-09	2016-11-16	Boehringer Ingelheim International GmbH	Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
UY30730A1 (es)	2006-12-04	2008-07-03	Mitsubishi Tanabe Pharma Corp	Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
ES2397664T3 (es)	2006-12-04	2013-03-08	Janssen Pharmaceutica, N.V.	Derivados de glucopiranósilo que contienen tienilo como antidiabéticos
EP1956023A1 (en)	2007-02-06	2008-08-13	Lonza Ag	Method for lithium exchange reactions
PE20090185A1 (es)	2007-03-22	2009-02-28	Bristol Myers Squibb Co	Formulaciones farmaceuticas que contienen un inhibidor sglt2
US20090047514A1 (en)	2007-08-15	2009-02-19	Allen David P	Thermal Activated Pressure Sensitive Adhesive and Method for Producing the Same and Product therewith
CL2008002425A1 (es)	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta.
TWI434691B (zh)	2007-08-23	2014-04-21	Theracos Inc	苄基苯衍生物及使用方法
JP5596545B2 (ja)	2007-09-10	2014-09-24	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｓｇｌｔの阻害物質として有用な化合物の製造方法
CL2008003653A1 (es)	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
PE20140960A1 (es)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
US9056850B2 (en) *	2008-10-17	2015-06-16	Janssen Pharmaceutica N.V.	Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en)	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
UA109883C2 (uk)	2009-10-14	2015-10-26		Спосіб отримання сполук для застосування як інгібіторів sglt2
SG185525A1 (en)	2010-05-11	2012-12-28	Janssen Pharmaceutica Nv	Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt

2009
- 2009-10-14 US US12/578,934 patent/US9056850B2/en active Active
- 2009-10-15 CN CN201310358939.0A patent/CN103467439B/zh active Active
- 2009-10-15 PT PT97369284T patent/PT2346888E/pt unknown
- 2009-10-15 PT PT121560353T patent/PT2455374T/pt unknown
- 2009-10-15 LT LTEP12156035.3T patent/LT2455374T/lt unknown
- 2009-10-15 WO PCT/EP2009/063503 patent/WO2010043682A2/en active Application Filing
- 2009-10-15 KR KR1020167017935A patent/KR101679593B1/ko active IP Right Grant
- 2009-10-15 CA CA2740853A patent/CA2740853C/en active Active
- 2009-10-15 PL PL12156035T patent/PL2455374T3/pl unknown
- 2009-10-15 JP JP2011531489A patent/JP6123111B2/ja active Active
- 2009-10-15 EA EA201170579A patent/EA021373B1/ru unknown
- 2009-10-15 HU HUE12156039A patent/HUE030868T2/en unknown
- 2009-10-15 PT PT121560395T patent/PT2457908T/pt unknown
- 2009-10-15 SI SI200931615A patent/SI2457908T1/sl unknown
- 2009-10-15 EP EP12156035.3A patent/EP2455374B1/en active Active
- 2009-10-15 KR KR1020117010834A patent/KR101724598B1/ko active IP Right Grant
- 2009-10-15 ES ES12156035T patent/ES2854598T3/es active Active
- 2009-10-15 EP EP12156039.5A patent/EP2457908B8/en active Active
- 2009-10-15 CA CA2946212A patent/CA2946212C/en active Active
- 2009-10-15 DK DK12156039.5T patent/DK2457908T3/da active
- 2009-10-15 BR BRPI0920356-7A patent/BRPI0920356B1/pt active IP Right Grant
- 2009-10-15 RS RS20210150A patent/RS61484B1/sr unknown
- 2009-10-15 EP EP09736928A patent/EP2346888B1/en active Active
- 2009-10-15 SI SI200932112T patent/SI2455374T1/sl unknown
- 2009-10-15 UA UAA201106134A patent/UA107450C2/uk unknown
- 2009-10-15 AU AU2009305413A patent/AU2009305413B2/en active Active
- 2009-10-15 ES ES12156039.5T patent/ES2611881T3/es active Active
- 2009-10-15 SI SI200930548T patent/SI2346888T1/sl unknown
- 2009-10-15 HU HUE12156035A patent/HUE052432T2/hu unknown
- 2009-10-15 DK DK12156035.3T patent/DK2455374T3/da active
- 2009-10-15 RS RS20170048A patent/RS55577B1/sr unknown
- 2009-10-15 LT LTEP12156039.5T patent/LT2457908T/lt unknown
- 2009-10-15 NZ NZ592204A patent/NZ592204A/xx unknown
- 2009-10-15 RS RS20130121A patent/RS52740B/en unknown
- 2009-10-15 MX MX2011004054A patent/MX2011004054A/es active IP Right Grant
- 2009-10-15 DK DK09736928.4T patent/DK2346888T3/da active
- 2009-10-15 CN CN201510944228.0A patent/CN105541814A/zh active Pending
- 2009-10-15 ES ES09736928T patent/ES2399959T3/es active Active
- 2009-10-15 PL PL12156039T patent/PL2457908T3/pl unknown
- 2009-10-15 PL PL09736928T patent/PL2346888T3/pl unknown
- 2009-10-15 CN CN2009801516486A patent/CN102264714A/zh active Pending
- 2009-10-16 AR ARP090103994A patent/AR073892A1/es active IP Right Grant
- 2009-10-16 TW TW104122678A patent/TW201613905A/zh unknown
- 2009-10-16 TW TW103123880A patent/TWI636981B/zh active
- 2009-10-16 TW TW098135070A patent/TWI588143B/zh active
2011
- 2011-04-12 IL IL212270A patent/IL212270A0/en unknown
- 2011-04-15 CL CL2011000849A patent/CL2011000849A1/es unknown
- 2011-05-16 ZA ZA2011/03587A patent/ZA201103587B/en unknown
2013
- 2013-03-22 HR HRP20130254AT patent/HRP20130254T1/hr unknown
- 2013-03-29 CY CY20131100267T patent/CY1113867T1/el unknown
- 2013-06-05 SM SM201300058T patent/SMT201300058B/xx unknown
2014
- 2014-06-17 JP JP2014124295A patent/JP5905926B2/ja active Active
2015
- 2015-06-10 IL IL239313A patent/IL239313A/en active IP Right Grant
2016
- 2016-03-09 JP JP2016045328A patent/JP2016117758A/ja active Pending
- 2016-11-01 HK HK16112527.9A patent/HK1224289A1/zh unknown
2017
- 2017-02-10 SM SM201700092T patent/SMT201700092B/it unknown
- 2017-02-17 HR HRP20170255TT patent/HRP20170255T1/hr unknown
- 2017-02-21 CY CY20171100236T patent/CY1118708T1/el unknown
2021
- 2021-02-09 HR HRP20210225TT patent/HRP20210225T1/hr unknown
- 2021-02-15 CY CY20211100125T patent/CY1123817T1/el unknown

Also Published As

Publication number	Publication date
EP2346888B1 (en)	2013-01-02
UA107450C2 (uk)	2015-01-12
EP2457908B8 (en)	2017-04-05
KR101724598B1 (ko)	2017-04-07
TWI588143B (zh)	2017-06-21
RS61484B1 (sr)	2021-03-31
PT2457908T (pt)	2017-03-02
IL212270A0 (en)	2011-07-31
AR073892A1 (es)	2010-12-09
CN103467439B (zh)	2016-11-23
ES2611881T3 (es)	2017-05-11
BRPI0920356B1 (pt)	2021-09-21
CN103467439A (zh)	2013-12-25
BRPI0920356A2 (pt)	2015-08-04
TW201613905A (en)	2016-04-16
EP2455374B1 (en)	2020-12-16
US9056850B2 (en)	2015-06-16
HK1224289A1 (zh)	2017-08-18
SI2455374T1 (sl)	2021-04-30
HUE030868T2 (en)	2017-06-28
CA2740853A1 (en)	2010-04-22
MX2011004054A (es)	2011-05-24
JP2014167030A (ja)	2014-09-11
IL239313A (en)	2017-07-31
KR20110086039A (ko)	2011-07-27
ZA201103587B (en)	2012-10-31
IL239313A0 (en)	2015-07-30
ES2854598T3 (es)	2021-09-22
PL2457908T3 (pl)	2017-08-31
JP6123111B2 (ja)	2017-05-10
WO2010043682A2 (en)	2010-04-22
CA2740853C (en)	2017-07-11
CA2946212C (en)	2018-05-22
SI2346888T1 (sl)	2013-05-31
PT2455374T (pt)	2021-01-20
EA021373B1 (ru)	2015-06-30
TWI636981B (zh)	2018-10-01
KR20160083144A (ko)	2016-07-11
CA2946212A1 (en)	2010-04-22
CN102264714A (zh)	2011-11-30
RS55577B1 (sr)	2017-05-31
TW201443033A (zh)	2014-11-16
CN105541814A (zh)	2016-05-04
LT2457908T (lt)	2017-03-10
LT2455374T (lt)	2021-05-10
EP2455374A1 (en)	2012-05-23
EP2457908A1 (en)	2012-05-30
NZ592204A (en)	2012-12-21
PL2346888T3 (pl)	2013-06-28
PL2455374T3 (pl)	2021-07-12
EA201170579A1 (ru)	2011-10-31
RS52740B (en)	2013-08-30
HRP20170255T1 (hr)	2017-04-07
HRP20130254T1 (en)	2013-06-30
HRP20210225T1 (hr)	2021-04-02
WO2010043682A3 (en)	2011-08-11
CY1113867T1 (el)	2016-07-27
EP2457908B1 (en)	2016-11-23
TW201026689A (en)	2010-07-16
PT2346888E (pt)	2013-02-27
AU2009305413B2 (en)	2015-07-09
US20100099883A1 (en)	2010-04-22
JP2016117758A (ja)	2016-06-30
KR101679593B1 (ko)	2016-11-25
ES2399959T3 (es)	2013-04-04
SI2457908T1 (sl)	2017-05-31
HUE052432T2 (hu)	2021-04-28
JP5905926B2 (ja)	2016-04-20
CY1118708T1 (el)	2017-07-12
JP2012505858A (ja)	2012-03-08
EP2346888A2 (en)	2011-07-27
CL2011000849A1 (es)	2011-08-05
DK2457908T3 (da)	2017-02-13
CY1123817T1 (el)	2022-05-27
DK2455374T3 (da)	2021-02-08
SMT201700092B (it)	2017-03-08
AU2009305413A1 (en)	2010-04-22
SMT201300058B (it)	2013-07-09

Publication	Publication Date	Title
DK2346888T3 (da)	2013-03-25	Fremgangsmåde til fremstilling af som SGLT-inhibitorer anvendelige forbindelser
DK2046767T3 (da)	2015-06-22	Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
DK2086944T3 (da)	2010-05-03	Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK2114886T3 (da)	2014-06-30	Fremgangsmåde til fremstilling af visse substituerede sulfiliminer
HK1144554A1 (en)	2011-02-25	Process for the preparation of compounds useful as inhibitors of sglt
DK2155838T3 (da)	2014-12-15	Fremgangsmåde til fremstilling af forgrenede carbonhydrider
DK3354650T3 (da)	2022-05-30	Forbindelser der er nyttige som inhibitorer af ATR-kinase
DK2139892T3 (da)	2011-12-12	Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer
DK2331547T3 (da)	2014-11-03	Pyrrolopyrimidinforbindelser som CDK-inhibitorer
DK2414362T3 (da)	2014-09-22	Pyrimidinsubstituerede purinforbindelser som kinaseinhibitorer
DK2204453T3 (da)	2013-06-10	Fremgangsmåde til celle-fri fremstilling af kemikalier
DK3301074T3 (da)	2019-11-11	Fremgangsmåde til fremstilling af aluminiumphosphat
DK2382232T3 (da)	2013-12-16	Fremgangsmåde til fremstilling af bivalirudin
BRPI0909270A2 (pt)	2015-08-11	Compostos de sirna para inibição de rtp801
DK2245000T3 (da)	2013-03-25	Fremgangsmåde til fremstilling af optisk aktive alfa-aminoacetaler
DK2379491T3 (da)	2013-04-08	Fremgangsmåde til syntese af amino-methyl-tetralinderivater
DK2403361T3 (da)	2013-04-08	Fremgangsmåde til fremstilling af carotinoid-opløsninger
DK2326648T3 (da)	2012-10-15	Fremgangsmåde til fremstillingen af carbapenemforbindelser
DK2121649T3 (da)	2013-05-06	Fremgangsmåde til fremstilling af benzofuran-2-carboxamider